D. E. Shaw & Co, founded by billionaire David E. Shaw, has reported its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) via a 13G filing with the US Securities and Exchange Commission. The filing showed that D. E. Shaw & Co. owns 3.75 million shares of BioCryst Pharmaceuticals, which represent 5.1% of the company’s outstanding stock. The position is higher than the 2.56 million shares that the fund reported in its last 13F filing.
Overall, BioCryst Pharmaceuticals saw 15 funds from our database holding shares at the end of December, which compares with 14 funds a quarter earlier. Among the investors we track, Baker Bros. Advisors, managed by Julian Baker and Felix Baker, owns the largest position in BioCryst, worth $146.7 million as of the end of December, followed by Peter Kolchinsky’s RA Capital Management with a $31.9 million stake. Other investors with similar optimism include, Daniel Gold’s QVT Financial and Bihua Chen’s Cormorant Asset Management. In addition, Jim Simons’ Renaissance Technologies initiated a $1.5 million position in BioCryst during the last three months of 2015.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|D. E. Shaw Co.||0||3,713,161||0||3,750,783||3,750,783||5.1%|
|David E. Shaw||0||3,713,161||0||3,750,783||3,750,783||5.1%|
Page 1 of 6 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
BioCryst Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.01
(Title of Class of Securities)
March 4, 2016
(Date of Event Which Requires Filing of
Check the following box to designate the rule pursuant to which
the Schedule is filed:
|[ ]||Rule 13d-1(b)|
|[ X ]||Rule 13d-1(c)|
|[ ]||Rule 13d-1(d)|
*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).